bl-7040
Nucleic acidexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2012 (NCT01506362)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Toll-like receptor 9AGONIST
TLR9 agonist
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- bl-7040
- bl-7040
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01506362 | Phase 2 | Mar 1, 2012 | BioLineRx, Ltd., Hebrew University, Technion University, Tel Aviv University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioLineRx, Ltd. | For profit | 1 | 1 | 1 | 2012 |
| Hebrew University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Technion University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Tel Aviv University | Academic/Hospital | 1 | 0 | 1 | 2012 |
4 organizations
Page 1 / 1